Among 996 patients in the Swiss Pulmonary Hypertension Registry, overall event-free survival was 84%, 72%, 64%, and 58% at 1 to 4 years, with improved survival for PAH and CTEPH diagnosed since 2008.
Observational (n=996)
Yes
Long-term data from the Swiss PH registry demonstrates that incident patients since 2000 are older and hemodynamically better, with improved survival for PAH and CTEPH diagnosed since 2008.
BACKGROUND: Registries are important for real-life epidemiology on different pulmonary hypertension (PH) groups. OBJECTIVE: To provide long-term data of the Swiss PH registry of 1998-2012. METHODS: PH patients have been classified into 5 groups and registered upon written informed consent at 5 university and 8 associated hospitals since 1998. New York Heart Association (NYHA) class, 6-min walk distance, hemodynamics and therapy were registered at baseline. Patients were regularly followed, and therapy and events (death, transplantation, endarterectomy or loss to follow-up) registered. The data were stratified according to the time of diagnosis into prevalent before 2000 and incident during 2000-2004, 2005-2008 and 2009-2012. RESULTS: From 996 (53% female) PH patients, 549 had pulmonary arterial hypertension (PAH), 36 PH due to left heart disease, 127 due to lung disease, 249 to chronic thromboembolic PH (CTEPH) and 35 to miscellaneous PH. Age and BMI significantly increased over time, whereas hemodynamic severity decreased. Overall, event-free survival was 84, 72, 64 and 58% for the years 1-4 and similar for time periods since 2000, but better during the more recent periods for PAH and CTEPH. Of all PAH cases, 89% had target medical therapy and 43% combination therapy. Of CTEPH patients, 14 and 2% underwent pulmonary endarterectomy or transplantation, respectively; 87% were treated with PAH target therapy. CONCLUSION: Since 2000, the incident Swiss PH patients registered were older, hemodynamically better and mostly treated with PAH target therapies. Survival has been better for PAH and CTEPH diagnosed since 2008 compared with earlier diagnosis or other classifications.
Mueller‐Mottet et al. (2015) conducted an observational in Pulmonary hypertension (n=996). Time of diagnosis vs. Earlier time of diagnosis was evaluated on Event-free survival (death, transplantation, endarterectomy or loss to follow-up). Among 996 patients in the Swiss Pulmonary Hypertension Registry, overall event-free survival was 84%, 72%, 64%, and 58% at 1 to 4 years, with improved survival for PAH and CTEPH diagnosed since 2008.